Literature DB >> 12390297

Effects of glutathione S-transferase inhibitors on nitroglycerin action in pig isolated coronary arteries.

Toshihiro Matsuzaki1, Mayuko Sakanashi, Junko Nakasone, Katsuhiko Noguchi, Kanako Miyagi, Makiko Sakanashi, Ichiro Kukita, Yoko Aniya, Matao Sakanashi.   

Abstract

1. The present study was designed to clarify the role of glutathione S-transferase (GST) in the vasorelaxation response and development of tolerance to nitroglycerin (GTN) using GST inhibitors. 2. In pig isolated coronary arteries, GST activity was significantly changed to 77 and 82, or 69% of the control level (100%) following treatment with bromosulphophthalein (BSP; 10-3 and 10-4 mol/L) or ethacrynic acid (ETA; 10-4 mol/L), both GST inhibitors, respectively, but not following treatment with 10-3 and 10-4 mol/L GTN (GST activity 97 and 98% of control, respectively). 3. In KCl-contracted coronary artery strips pre-incubated with 10-5 and 10-4 mol/L GTN, 10-4 and 10-3 mol/L BSP or 10-4 mol/L ETA, concentration-dependent relaxations produced by GTN were significantly decreased compared with control. 4. 8-Bromo cGMP (8-Br-cGMP), a membrane-permeable cGMP analogue, produced concentration-dependent relaxations in GTN-pretreated arterial strips that were identical to control responses. However, there was weak but significant decrease in concentration-dependent relaxations in response to 8-Br-cGMP in BSP- and ETA-pretreated arteries. 5. The cGMP content in coronary arteries was significantly increased with GTN, GTN + BSP or GTN + ETA to similar high levels compared with control. 6. The results of the present study show that BSP and ETA decrease GTN- and 8-Br-cGMP-induced vasorelaxation, but have no effect on the GTN-induced increase in cGMP content in coronary arteries, suggesting a possibility that the GST inhibitors may have depressant actions on GTN- and 8-Br-cGMP-induced vasorelaxation through direct inhibition of the vasorelaxation of vascular smooth muscle themselves, in addition to having inhibitory effects GST activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390297     DOI: 10.1046/j.1440-1681.2002.03776.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  4 in total

1.  Nitroglycerin drives endothelial nitric oxide synthase activation via the phosphatidylinositol 3-kinase/protein kinase B pathway.

Authors:  Mao Mao; Varadarajan Sudhahar; Kristine Ansenberger-Fricano; Denise C Fernandes; Leonardo Y Tanaka; Tohru Fukai; Francisco R M Laurindo; Ronald P Mason; Jeannette Vasquez-Vivar; Richard D Minshall; Krisztian Stadler; Marcelo G Bonini
Journal:  Free Radic Biol Med       Date:  2011-10-07       Impact factor: 7.376

2.  Various intracellular compartments cooperate in the release of nitric oxide from glycerol trinitrate in liver.

Authors:  Andrey V Kozlov; Barbara Dietrich; Hans Nohl
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

3.  Effect of Shenmai injection on preventing the development of nitroglycerin-induced tolerance in rats.

Authors:  Qian Zhou; Yan Sun; Wangxiao Tan; Xiao Liu; Yuchen Qian; Xianghui Ma; Ting Wang; Xiaoying Wang; Xiumei Gao
Journal:  PLoS One       Date:  2017-04-28       Impact factor: 3.240

4.  Glutathione-S-Transferases as Potential Targets for Modulation of Nitric Oxide-Mediated Vasodilation.

Authors:  Tiffany M Russell; Des R Richardson
Journal:  Biomolecules       Date:  2022-09-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.